BROSSARD, Quebec, March 27, 2019 (GLOBE NEWSWIRE) -- DIAGNOS Inc. (“DIAGNOS” or “the Corporation”) (TSX Venture: ADK), (DGNOF), a leader in early detection of critical health issues through the use of its proprietary FLAIRE platform based on Artificial Intelligence (AI), announces today the signing of a memorandum of understanding to establish a framework between one hospital in the US and DIAGNOS.
Under the terms of a mutual non-disclosure agreement, the name of the hospital can’t be disclosed. The hospital is engaged and specializes in the medical field of stroke and related cardiological issues. The hospital has one of the largest databases in the world for stroke related patients. DIAGNOS will utilize this database to finalize the development and validation for CARDIO.
CARDIO is an application that predicts the future risk of a patient having a stroke or other conditions that may lead to a stroke. ‘’We are honored to form this relationship with a hospital and team of clinicians that are truly experts in the field of stroke. Using our FLAIRE platform we are able to analyse the retina and derive the key features that predict a stroke. Having access to the thousands of medical records from our hospital partner will enable DIAGNOS to finish the development and testing of the application. The screening will be done with the same commercial fundus camera used for identifying retinopathy with diabetic patients’’, said Dr. Reid Maclellan, director at DIAGNOS.
The Corporation is also announcing that a new date of April 10th, 2019 has been fixed for the meeting of the Debentureholders initially scheduled for April 4th, 2019 as stated in the Corporate Reorganization press release of March 11th, 2019. The decision of rescheduling the meeting date to April 10th, 2019 was undertaken to allow the Corporation to efficiently comply with the mailing of meeting material requirements.
DIAGNOS is a publicly-traded Canadian corporation with a mission of early detection of critical health issues through the use of its Artificial Intelligence (“AI”) tool CARA (Computer Assisted Retina Analysis). CARA is a tele-ophthalmology platform that integrates with existing equipment (hardware and software) and processes at the point of care. CARA’s Artificial Intelligence image enhancement algorithms make standard retinal images sharper, clearer and easier to read. CARA is accessible securely over the internet, and is compatible with all recognized image formats and brands of fundus cameras, and is EMR compatible. CARA is a cost-effective tool for screening large numbers of patients in real-time. CARA complies with local regulations, is FDA cleared for commercialization in the United States of America, is Health Canada licensed for commercialization in Canada and is CE marking compliant in Europe.
For further information, please contact:
|Mr. André Larente, President|
|Tel: 450-678-8882 ext. 224|
This news release contains forward-looking information. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in these statements. DIAGNOS disclaims any intention or obligation to publically update or revise any forward-looking information, whether as a result of new information, future events or otherwise. The forward-looking information contained in this news release is expressly qualified by this cautionary statement.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.